Cannabidiol and Its Effects on Patients with COVID-19 Infection

Kuntzman et al., Israel Medical Association Journal, 27:2, Feb 2025
Mortality 77% improvement lower risk ← → higher risk ICU admission 57% Hospitalization time 22% Cannabidiol  Kuntzman et al.  LATE TREATMENT RCT Is late treatment with cannabidiol beneficial for COVID-19? Double-blind RCT 10 patients in Israel Lower mortality with cannabidiol (not stat. sig., p=0.3) c19early.org Kuntzman et al., Israel Medical Associ.., Feb 2025 0 0.5 1 1.5 2+ RR
RCT 10 hospitalized COVID-19 patients showing potential benefit with sublingual cannabidiol (CBD) oil. There was only 7 patients in the treatment arm and 3 in the placebo group. CBD-treated patients showed a trends toward lower inflammatory cytokine levels including IL-6, IL-10, TNF-α, and C-reactive protein, though none reached statistical significance.
Important missing comments or errors? Let us know.
risk of death, 76.9% lower, RR 0.23, p = 0.30, treatment 0 of 7 (0.0%), control 1 of 3 (33.3%), NNT 3.0, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of ICU admission, 57.1% lower, RR 0.43, p = 1.00, treatment 1 of 7 (14.3%), control 1 of 3 (33.3%), NNT 5.2.
hospitalization time, 22.4% lower, relative time 0.78, p = 0.61, treatment mean 5.9 (±5.13) n=7, control mean 7.6 (±3.0) n=3.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kuntzman et al., 28 Feb 2025, Double Blind Randomized Controlled Trial, Israel, peer-reviewed, 3 authors.
$0 $500 $1,000+ Efficacy vs. cost for COVID-19 treatment protocols c19early.org December 2025 Israel United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Saudi Arabia Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Bosnia-Herzegovina Ukraine Côte d'Ivoire Bulgaria Greece Slovakia Singapore Iceland New Zealand Czechia Mongolia Hong Kong Belarus Qatar Panama Serbia CAR Israel favored high-profit treatments.The average efficacy of treatments was moderate.High-cost protocols reduce early treatment, andforgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
$0 $500 $1,000+ Efficacy vs. cost for COVID-19treatment protocols worldwide c19early.org December 2025 Israel United Kingdom Russia USA Sudan Angola Colombia Kenya Mozambique Pakistan Argentina Vietnam Peru Philippines Spain Brazil Italy France Japan China Uzbekistan Nepal Ethiopia Iran Ghana Mexico South Korea Germany Bangladesh Algeria Morocco Yemen Poland India DR Congo Madagascar Thailand Uganda Venezuela Nigeria Egypt Bolivia Taiwan Zambia Fiji Ukraine Côte d'Ivoire Eritrea Bulgaria Greece Slovakia Singapore New Zealand Malawi Czechia Belarus Qatar Panama Serbia Syria Israel favored high-profit treatments.The average efficacy was moderate.High-cost protocols reduce early treatment,and forgo complementary/synergistic benefits. More effective More expensive 75% 50% 25% ≤0%
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 200,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0